190 related articles for article (PubMed ID: 38014918)
1. A comparative safety review of targeted therapies for acute myeloid leukemia.
Dalgetty M; Leurinda C; Cortes J
Expert Opin Drug Saf; 2023; 22(12):1225-1236. PubMed ID: 38014918
[TBL] [Abstract][Full Text] [Related]
2. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
Bazinet A; Assouline S
Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
[No Abstract] [Full Text] [Related]
3. Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV; Abedin SM; Atallah E
Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
6. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
7. Novel therapies for AML: a round-up for clinicians.
Swaminathan M; Wang ES
Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1389-1400. PubMed ID: 33412978
[No Abstract] [Full Text] [Related]
8. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
10. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy.
Marchetti M; Albertin L; Limberti G; Canicattì M
Expert Opin Pharmacother; 2022 Feb; 23(2):263-272. PubMed ID: 34886738
[TBL] [Abstract][Full Text] [Related]
12. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
[TBL] [Abstract][Full Text] [Related]
14. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
15. Will new agents impact survival in AML?
Rowe JM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
[TBL] [Abstract][Full Text] [Related]
16. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
17. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
[TBL] [Abstract][Full Text] [Related]
18. Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.
Yılmaz U; Bulan B; Belli Ç; Eşkazan AE
Expert Rev Hematol; 2022 May; 15(5):423-429. PubMed ID: 35536916
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
20. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
